Federal contract award
75F40122C00146
BAA TOXWP 118/CTP-2022-112800 -EVALUATE AND PROMOTE THE USE OF CELL- AND TISSUE-BASED ASSAYS THAT MORE ACCURATELY REPRESENT HUMAN SUSCEPTIBILITY THAN ANIMAL MODELS TO ADVERSE REACTIONS AND PREDICT THRESHOLD OF TOXICOLOGICAL CONCERNS RESULTING FROM EX
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $2.0M |
| Current contract value | $2.0M |
| Potential contract value / ceiling | $2.0M |
| Start date | Sep 28, 2022 |
| Current end date | Sep 29, 2025 |
| Potential end date | Sep 29, 2026 |
| Latest award activity | Aug 12, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 12, 2025 | P00001 | $0 | NO-COST EXTENSION FOR IN VITRO ASSESSMENT OF CHEMICAL MIXTURE-INDUCED AIRWAY INFLAMMATION IN HEALTHY AND DISEASED LUNGS. |
| Sep 28, 2022 | 0 | $2.0M | BAA TOXWP 118/CTP-2022-112800 -EVALUATE AND PROMOTE THE USE OF CELL- AND TISSUE-BASED ASSAYS THAT MORE ACCURATELY REPRESENT HUMAN SUSCEPTIBILITY THAN ANIMAL MODELS TO ADVERSE REACTIONS AND PREDICT THRESHOLD OF TOXICOLOGICAL CONCERNS RESULTING FROM EX |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 20, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 20, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.